Introduction (first heading)
Migraine is an episodic neurovascular disorder characterized by repeated attacks of headache, autonomic dysfunction, and gastrointestinal symptoms (1) . Some patients experience an aura, manifesting as transient neurological symptoms that usually last less than 60 minutes, preceding attacks. Migraine is a common disorder, with a prevalence of 12% in the adult population (6% in men and 18% in women) and 4% in children. It has a strong impact on quality of life. The World Health Organization has ranked migraine as one of the most disabling of the chronic diseases (2).
Significant progress has been made in our understanding of migraine pathophysiology.
Migraine is now considered a primary CNS disorder with secondary effects on meningeal blood vessels (1) . The treatment of acute migraine attacks has improved dramatically with the introduction of the 5-HT 1B/1D agonists, known as the triptans. The preventive treatment of migraine has been neglected and, due to the relatively low efficacy and high adverse event (AE) rates of previously available preventive medicines, not satisfactory for many patients.
In this review we describe recent advances in the treatment of migraine, including neurotoxins as a novel approach to migraine prevention.
Botulinum toxin (first heading)
Botulinum toxin (BTX) is a potent neurotoxin produced by the anaerobic bacterium in botulism -an acute, potentially fatal muscle paralysis (5) . Over the last two decades, BTX has been used to treat various disorders associated with increased muscle tone (6, 7) . Recently, its efficacy in the treatment of headaches and other pain syndromes has been demonstrated.
Structure and Preparations (second heading)
BTX belongs to the clostridial neurotoxin family and exists as seven antigenicallydistinct serotypes (A-G) (3) . The toxin is non-covalently associated with non-toxic proteins. In its purified form, it is a ~150 kDa polypeptide that consists of two subunits, a light chain and a heavy chain, linked by a disulfide bond. The light chain acts as a zincdependent endopeptidase. The heavy chain contains two domains. One, in the C-terminal (H C ), is the ganglioside-binding domain, which has a key role in binding of the toxin to the target cell membrane and its internalization. The other, in the N-terminal (H N ), is the translocation domain that promotes penetration of the light chain through the endosomal membrane into the cytosol. Since BTX is a protein of non-human origin, it may evoke antibody formation (4, 9) .
BTX type A (BTX-
Once neutralizing antibodies are present, the efficacy of the toxin is lost (10) . The reported prevalence of treatment resistance due to antibody formation is variable and depends on the assay used for antibody detection, the patient population, and the treatment protocol. Using an older formulation, it was estimated to occur in at least 5%-10% of patients with cervical dystonia (11) . Factors that increase the risk for antibody formation include higher doses and short intervals between doses (12) (13) (14) . With the new formulation and the relatively low doses used in migraine treatment (see below), this complication is unlikely to occur. Recommendations for minimizing immunoresistance include using the lowest effective dose at the longest possible intervals and avoiding booster injections (4) . When resistance to one BTX serotype develops, switching to a different serotype may restore the therapeutic response (10) . This response, however, may be only temporary. In a recent study, ten patients with antibody-mediated therapeutic failure to BTX-A were given BTX-B (NeuroBloc   ®   ) . After an initial response, six patients developed secondary therapeutic failure with documented antibodies to BTX-B (15).
A new low-molecular-weight BTX-A has recently been developed and shown to be effective in an animal model (16) . This novel toxin may be less immunogenic than the conventional BTX-A.
Mechanism of Action (second heading)
BTX affects the nervous system through a multi-stage process that results in blocking neurotransmitter release (3, 4, 17) . The toxin binds to the target nerve terminal through its 
Effect at the Neuromuscular Junction (third heading)
The main site of action of BTX is the neuromuscular junction. By interfering with acetylcholine release from the pre-synaptic axon terminal at this site, BTX causes a dosedependent and reversible muscle relaxation. Axonal sprouting, which occurs following BTX entrance into the cell, causes termination of the toxin effect in 2 to 6 months.
Effect on the Autonomic Nervous System (third heading)
Botulism is known to be associated with autonomic nervous system dysfunction (5). BTX affects cholinergic synapses in both sympathetic and parasympathetic pathways. By acting at these sites, the toxin was shown to reduce sweat secretion in patients with hyperhidrosis and to improve bladder function in patients with detrusor sphincter dyssynergia (18, 19 BTX may also act via afferent mechanisms (20) . In animal models BTX was shown to reduce spindle afferent discharges, suggesting a direct effect on gamma motor nerve endings (21) . It also caused atrophy of both intrafusal and extrafusal muscle fibers when injected into rats (22) .
Effects on the Central Nervous System (third heading)
There is increasing evidence that BTX affects the CNS (23) . In earlier animal studies, retrograde transport of the toxin into the CNS was suggested (24) . More recently, however, it was shown that only breakdown products of the toxin were transported in a retrograde manner (25) . Janicki & Habermann found that BTX inhibits the release of methionine-enkephalin-like material in the rat striatum in vitro (26) . However, little evidence currently exists for the penetration of functional toxin into the CNS in humans. caused by BTX may also cause changes in sensory processing at higher levels of the nervous system; 3. BTX may suppress neurogenic inflammation, which has been implicated in the pathogenesis of migraine and other pain syndromes; 4. BTX may affect the release of neurotransmitters other than acetylcholine. There is evidence that it inhibits the release of substance P in vitro (36, 37) . More evidence for this theory comes from an in vivo study by Cui et al, who showed that the effect of BTX on pain behavior in the rat formalin model is associated with reduced glutamate release (38) .
Clinical Uses -General (second heading)
Botulinum toxin was shown to be effective in the treatment of a variety of disorders (6, 7, 39) . Its first clinical use was for the treatment of strabismus (40) . It has also been used extensively for various forms of dystonia and other conditions associated with increased muscle tone (7, 41) . Other conditions responsive to treatment with BTX include achalasia, spastic bladder, and hyperhidrosis (18, 42) .
Data shows that BTX is effective in the treatment of various pain syndromes, including neuropathic pain, low back pain, and whiplash-associated disorders (43) (44) (45) . Its use in migraine and other types of chronic headaches was recently studied and showed positive results (29, (46) (47) (48) (49) 
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The beneficial effect of BTX-A in migraine treatment was first noted in patients who were given the toxin for the treatment of facial wrinkles (50) . Since then, an increasing number of studies have been conducted to examine the efficacy of BTX-A, and more recently BTX-B, as a migraine preventive drug (Table) .
Botulinum Toxin Type A (BTX-A) (third heading)
Efficacy and Tolerability (fourth heading) Although total number of days with headache was not reduced, the character of the pain changed to a moderate, non-throbbing headache responsive to standard analgesics.
Several other retrospective studies have shown efficacy for BTX-A in migraine prevention (56) (57) (58) . Other studies of patients with chronic daily headache, many of whom have chronic migraine, showed only a mild or no response to BTX (59, 60).
Safety Considerations (fourth heading)
With clinical experience for over two decades, BTX-A has proved to be a remarkably safe drug. Based on animal studies, the lethal dose in humans is estimated at approximately 3000 units (4). The doses used for migraine treatment (25-100 units) are unlikely to be toxic. An antitoxin is available in the event of accidental overdose (61) .
BTX should be used with caution in patients with neuromuscular junction diseases (e.g. myasthenia gravis). It is contraindicated in patients who take aminoglycosides, which interfere with neuromuscular transmission (62) . Since there is little data on the safety of BTX in pregnant and lactating women, it is not recommended for use in these 
Other New Approaches to Migraine Treatment (first heading)
Recent advances in the research of migraine pathophysiology have led to new concepts in migraine prevention (1, 66) . Migraine is currently viewed as a neurovascular disorder with a CNS generator (1) . Therefore, the current focus in migraine prevention is on attempting to modulate central neurotransmitter systems.
Topiramate (second heading)
Anticonvlsants are being increasingly used for migraine prevention. Topiramate is a structurally-unique anticonvulsant derived from D-fructose (67) . In addition to seizure 
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Significantly more patients treated with topiramate 100 mg/day had R 50% reduction in migraine frequency (responders) compared with placebo-treated patients (54% vs 23%).
Topiramate treatment was also associated with a reduction in the mean monthly migraine days and a decrease in the consumption of acute pain medications. The 200 mg dose was not significantly more effective than the 100 mg dose. The onset of drug effect was observed by the end of the first month of treatment. Topiramate was well tolerated. The most common adverse events were paresthesias, taste change, anorexia, fatigue, and nausea. Cognitive adverse events occurred in 19% of patients taking the 100 mg dose, but led to withdrawal in only 4%. In contrast to many other migraine preventive drugs, that cause weight gain, topiramate treatment was associated with an average of 3.8% weight loss.
A similarly-designed study that included 483 migraine patients (the MIGR-002 study)
was recently completed (76) . Patients were randomized to receive either topiramate (50, 100 or 200 mg/day) or placebo. Patients treated with topiramate 100 mg/day had a mean decrease of 2.3 episodes/month in migraine frequency, compared with a decrease of 1.1 episodes/month for patients receiving placebo. Responder rates (as defined above) were significantly higher in the topiramate 100 mg group (49%) compared with placebo (23%). As in the MIGR-001 study, the 100 mg dose had the most favorable efficacy/tolerability profile. Topiramate was safe and generally well-tolerated. Side effects were similar to those found in the previous study. There was an average weight loss of 3.3% of body weight in the topiramate 100 mg group. The third trial (MIGR-003 study), which compared topiramate to propranolol and placebo, has recently been completed but results are still not available. 18 Young et al evaluated the outcome of 74 migraine patients treated with topiramate in a case series study (73) . Twenty four patients had episodic migraine and fifty had chronic migraine. The mean dose was 208 mg/day and treatment was given for at least six weeks.
Topiramate treatment resulted in a mean decrease of seven days/month with headache (from 21.6 to 13.6). The responder rate to topiramate (as defined above) was 44.6%
(58.3% for episodic migraine and 38.0% for chronic migraine). Headache severity was also significantly reduced. Adverse events were usually mild to moderate and included paresthesias, cognitive difficulties, dizziness, and nausea. Patients with comorbid depression had a similar outcome to those who were not depressed.
Another retrospective study was conducted by Mathew et al to evaluate the efficacy of topiramate in the treatment of migraine (74) . Topiramate was given as add-on therapy for chronic migraine patients and as monotherapy for episodic migraine patients. The mean daily dose of topiramate was 87.5 mg and the mean duration of treatment was 8.4
months. In patients with chronic migraine, mean days with migraine per 28 days decreased from 6.3 to 3.7. Headache severity, consumption of acute pain medications, and MIDAS scale values also decreased significantly in this group. Patients with episodic migraine also had a significant decrease in headache severity and in monthly migraine days (from 5.8 to 1.9 per 28 days). In this study, which also included cluster headache patients, topiramate was well tolerated, with only 8/178 patients discontinuing treatment.
Several other studies have demonstrated topriamate's efficacy in migraine treatment (77, 78) . These results show that topiramate is effective for migraine prevention. The doses epilepsy, making cognitive side effects less of a concern. Weight loss, rather than the weight gain seen with many other preventive treatments, is a major benefit.
Angiotensin II Receptor Blockade (second heading)
Several reports on the efficacy of angiotensin converting enzyme (ACE) inhibitors for migraine prevention have been published (79, 80) . Angiotensin receptor antagonists block the renin-angiotensin system without the common side effects caused by ACE inhibitors (e.g. coughing and angioneurotic edema). Recently, the efficacy of candesartan, an angiotensin II type 1 (AT 1 ) receptor blocker, in migraine prevention was evaluated in a placebo-controlled study that included sixty patients (81) . Patients were given candesartan 16 mg/day or placebo for two 12-week periods in a cross-over design.
The mean number of days with headache during a 12-week period was significantly lower with candesartan than with placebo (13.6 vs 18.5). Candesartan also lowered headache severity, level of disability, and days of sick leave. Candesartan was very well tolerated, with a tolerability profile similar to that of placebo. The mechanism of action of this drug in migraine prevention is currently unknown. Angiotensin II affects cerebral blood flow through AT 1 receptors (82) . It was also shown to modulate the activity of various neurotransmitters, including serotonin, dopamine, and melatonin (83, 84) . The number of drugs available for migraine preventive treatment is increasing. More data are available regarding the efficacy of various drugs, enabling a more rational, rather than the previously-used empiric, therapeutic approach.
There is increasing evidence for the efficacy of BTX-A in the treatment of migraine. Its long duration of action and high tolerability make it especially appealing for patients whose compliance to orally-administered drugs is poor. The anticonvulsant topiramate is effective for migraine prevention at relatively low doses, making cognitive side-effects less of a concern. It has the beneficial added result of weight loss. Angiotensin II receptor blockade is a new approach to migraine prevention that needs to be further tested. 
